OrbiMed Reduces Stake in Enliven Therapeutics by Over 1%
ELVN has more than doubled off its 52-week low of $14.785 on elevated volume (2.1× avg).
Summary
OrbiMed, a major institutional investor, disclosed a reduction in its stake in Enliven Therapeutics by selling approximately $40.4 million worth of shares in June 2025, decreasing its beneficial ownership to 9.5%.
Key Events · Ownership and Investor Activity · ELVN
-
Significant Stake Reduction
OrbiMed Advisors and its affiliates reported selling 891,255 shares of Enliven Therapeutics common stock.
-
Substantial Transaction Value
The sales, which occurred in June 2025, totaled approximately $40.4 million at an average price of $45.34 per share.
-
Ownership Below 10%
Following these transactions, OrbiMed's beneficial ownership decreased from over 10% to 9.5% of the outstanding shares.
Analysis · ELVN · Life Sciences
OrbiMed, a significant institutional investor, reported a reduction in its beneficial ownership of Enliven Therapeutics common stock by over 1% of the outstanding shares. While the sales of approximately $40.4 million worth of shares occurred in June 2025, this amendment formally discloses the change in their stake, bringing their total ownership to 9.5%. This disposition by a major holder occurred before the company's recent positive Phase 1 data and large public offering.
At the time of this filing, ELVN was trading at $47.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $14.79 to $49.94. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.